Abstracts Archive - Page 727 of 2425 - ACR Meeting Abstracts

Abstract Number: 1497 • ACR Convergence 2020
COVID-19 in Pregnant Patients with Rheumatic Disease: Data from the COVID-19 Global Rheumatology Alliance
Bonnie Bermas¹, Megan Clowse², Milena Gianfrancesco³, Jonathan Hausmann⁴, Pedro M Machado⁵, Emily Sirotich⁶, Helen Robinson⁷, Anja Strangfeld⁸, Jinoos Yazdany⁹ and Philip Robinson¹⁰, ¹UTSouthwestern.edu, Dallas, TX, ²Duke University, Chapel Hill, NC, ³University of California, San Francisco, San Francisco, CA, ⁴Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ⁵University College London, London, United Kingdom, ⁶McMaster University, Hamilton, ON, Canada, ⁷University of Queensland School of Medicine, HERSTON, Queensland, Australia, ⁸German Rheumatism Research Center, Berlin, Germany, ⁹UCSF, San Francisco, CA, ¹⁰University of Queensland, Herston, Queensland, Australia
Background/Purpose: The impact of COVID-19 on pregnancy in patients with rheumatic disease is unknown. We describe COVID-19 outcomes in pregnant rheumatic disease patients reported to…
Abstract Number: 1496 • ACR Convergence 2020
Outcomes of an Evidence Based Guideline for the Treatment of Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome
Kacie Hoyt¹, Olha Halyabar², Joseph Han³, Siobhan Case⁴, Margaret Chang¹, Craig Platt⁵, Ezra Cohen¹, Megan Day-Lewis⁵, Fatma Dedeoglu¹, Jonathan Hausmann⁶, Erin Janssen², Pui Lee⁷, Jeffrey Lo¹, Gregory Priebe⁵, Mindy Lo¹, Esra Meidan⁸, Peter Nigrovic⁹, Jordan Roberts¹, Mary Beth Son¹, Robert Sundel², Mark Gorman¹, Barbara Degar¹⁰, Melissa Hazen¹ and Lauren Henderson¹¹, ¹Boston Children's Hospital, Boston, MA, ²Children's Hospital/Boston Medical Center, Boston, MA, ³Mount Sinai School of Medicine, New York, NY, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Boston Children's Hospital, Boston, ⁶Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ⁷1.Boston Children's Hospital;2.Brigham and Women's Hospital;3.Harvard Medical School, Newton, MA, ⁸Boston Children's Hospital, Somerville, MA, ⁹Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston, ¹⁰Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, ¹¹Boston Children's Hospital, Watertown, MA
Background/Purpose: Rapid identification of HLH/MAS coupled with a multidisciplinary approach to management is essential to improve patient outcomes. We describe our experience with a newly…
Abstract Number: 1502 • ACR Convergence 2020
Composite of Relevant Endpoints for Sjögren’s Syndrome (CRESS)
Suzanne Arends¹, Liseth de Wolff², Jolien van Nimwegen³, Gwenny Verstappen², Jelle Vehof², Arjan Vissink⁴, Neelanjana Ray⁵, Frans Kroese² and Hendrika Bootsma², ¹University Medical Centre Groningen and Medical centre Leeuwarden, Groningen, Netherlands, ²University Medical Centre Groningen, Groningen, Netherlands, ³University Medical Center Groningen, Groningen, Netherlands, ⁴University Medical Centre Groningen, Leek, Netherlands, ⁵Bristol-Myers Squibb, Lawrenceville
Background/Purpose: Several recent randomized controlled trials that used the validated ESSDAI as primary endpoint failed, partly explained by relatively large response rates in the placebo…
Abstract Number: 1504 • ACR Convergence 2020
Four Distinct Symptom-Based Clusters Identified from the Sjӧgren’s Foundation Survey
Sara McCoy¹, Christie Bartels², Miguel Woodham¹, Noah Maerz¹, Esen Akpek³, Ian Saldanha⁴, Matthew Makara⁵ and Alan Baer⁶, ¹University of Wisconsin, Madison, ²University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI, ³Johns Hopkins University, Baltimore, ⁴Brown University, Providence, ⁵Sjogren's Syndrome Foundation, Reston, ⁶Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Relief of symptoms is a sine qua non for successful drug development in Sjӧgren’s syndrome (SS). However, symptom-based patient experience is understudied, particularly how…
Abstract Number: 1499 • ACR Convergence 2020
The Frequency of Contraception Documentation in Women with Lupus and Rheumatoid Arthritis Within the RISE Registry
Megan Clowse¹, Jing Li², Amanda Eudy³, Mehret Birru Talabi⁴ and Gabriela Schmajuk⁵, ¹Duke University, Chapel Hill, NC, ²University of California, San Francisco, San Francisco, CA, ³Duke University, Durham, NC, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵University of California, San Francisco, Atherton, CA
Background/Purpose: Several of the most commonly prescribed anti-rheumatic medications for women with rheumatic disease are known teratogens, posing a risk for pregnancy loss and birth…
Abstract Number: 1494 • ACR Convergence 2020
Patient-Reported Adverse Events, Quality of Life and Treatment Adherence in Juvenile Idiopathic Arthritis: Analysis of Two Large International Cohorts
Alessandra Alongi¹, Maria Trachana², Valda Stanevicha³, Laura Marinela Ailioaie⁴, Elena Tsitsami⁵, Angelo Ravelli⁶, Alessandro Consolaro⁶ and Nicolino Ruperto⁷, ¹IRCCS Istituto Giannina Gaslini, Genoa, Italy, ²Aristotle University of Thessaloniki, Thessaloníki, Greece, ³Riga Stradins University, Riga, Latvia, ⁴Alexandru Ioan Cuza University of Iasi, Iasi, Romania, ⁵Aghia Sophia Childrens Hospital, Athens, Greece, ⁶Università degli Studi di Genova, Genoa, Italy, ⁷Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Juvenile idiopathic arthritis (JIA) patients may experience significant medication-related adverse effects (AEs), which may adversely affect health-related quality of life (HRQOL), daily activities and…
Abstract Number: 1507 • ACR Convergence 2020
Longitudinal Analysis of ANA Assay Performance in SLE from the SLICC Inception Cohort
May Choi¹, Ann Clarke², Karen Costenbader³, Murray Urowitz⁴, John Hanly⁵, Caroline Gordon⁶, Yvan St. Pierre⁷, Sang-Cheol Bae⁸, Juanita Romero-Díaz⁹, F Jorge Sanchez-Guerrero¹⁰, Sasha Bernatsky¹¹, Daniel Wallace¹², David Isenberg¹³, Anisur Rahman¹⁴, Joan Merrill¹⁵, Paul Fortin¹⁶, Dafna Gladman¹⁷, Ian Bruce¹⁸, Michelle Petri¹⁹, Ellen M Ginzler²⁰, Mary Anne Dooley²¹, Rosalind Ramsey-Goldman²², Susan Manzi²³, Andreas Jönsen²⁴, Graciela Alarcón²⁵, Ronald F Van Vollenhoven²⁶, Cynthia Aranow²⁷, Meggan Mackay²⁸, Guillermo Ruiz-Irastorza²⁹, S. Sam Lim³⁰, Murat Inanc³¹, Kenneth Kalunian³², Søren Jacobsen³³, Christine Peschken³⁴, Diane Kamen³⁵, Anca Askanase³⁶ and Marvin Fritzler³⁷, ¹Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²University of Calgary, Calgary, Canada, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴University Health Network, University of Toronto, Toronto, ON, Canada, ⁵Dalhousie University, Halifax, NS, Canada, ⁶University of Birmingham, Birmingham, England, United Kingdom, ⁷McGill University, Montreal, Canada, ⁸Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ¹⁰University Health Network/Sinai Health system, Toronto, ON, Canada, ¹¹The Research Institute of the McGill University Health Centre, Montreal, ON, Canada, ¹²Cedars-Sinai Medical Center/UCLA, Los Angeles, CA, ¹³Centre for Rheumatology, University College London and Department of Rheumatology, University College Hospital, London, United Kingdom, ¹⁴University College London, London, United Kingdom, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, ¹⁶CHU de Quebec - Universite Laval, Quebec, Canada, ¹⁷Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ¹⁸Centre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ¹⁹Johns Hopkins University School of Medicine, Timonium, MD, ²⁰SUNY Downstate Health Sciences University, Brooklyn, ²¹University of North Carolina, Chapel Hill, NC, ²²Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²³Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ²⁴Lund University, Lund, Sweden, ²⁵Division of Clinical Immunology and Rheumatology, Department of Medicine, School of Medicine, The University of Alabama at Birmingham; Department of Medicine, School of Medicine; Universidad Peruana Cayetano, Heredia, Alabama, ²⁶Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ²⁷Feinstein Institutes for Medical Research, Manhasset, NY, ²⁸Feinstein Institute for Medical Research, Manhasset, NY, ²⁹Hospital Universitario Cruces, Barakaldo, Spain, ³⁰Emory University, Atlanta, GA, ³¹Department of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ³²University of California San Diego, La Jolla, CA, ³³University of Copenhagen, Copenhagen, Denmark, ³⁴Departments of Medicine and Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ³⁵Medical University of South Carolina, Charleston, SC, ³⁶Columbia University College of Physicians and Surgeons, New York, NY, ³⁷Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Anti-nuclear antibodies (ANA) are important biomarkers for the diagnosis and classification of systemic lupus erythematosus (SLE). However, emerging data from cross-sectional studies suggest variation…
Abstract Number: 1510 • ACR Convergence 2020
Platelet-bound C4d Is Associated with Platelet Activation and Arterial Thrombotic Events
Yevgeniya Gartshteyn¹, Adam Mor², Daichi Shimbo², Leila Khalili³, Teja Kapoor⁴, Laura Geraldino-Pardilla⁵, Roberta Vezza Alexander⁶, Thierry Dervieux⁷ and Anca Askanase², ¹Columbia University College of Physicians and Surgeons, Glen Rock, NJ, ²Columbia University College of Physicians and Surgeons, New York, NY, ³Columbia University Medical Center, New Haven, CT, ⁴Columbia University College of Physicians and Surgeons, Leonia, NJ, ⁵Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, ⁶Exagen Inc, Vista, CA, ⁷Prometheus Biosciences Inc, Irvine, CA
Background/Purpose: Platelets have a well-defined role in arterial thrombosis, and platelet-bound complement activation products (PC4d) correlate with vascular thromboses in patients with Systemic Lupus Erythematosus…
Abstract Number: 1511 • ACR Convergence 2020
Clinical Features and Select Dysregulated Immune Parameters Distinguish Blood Relatives Who Remain Clinically Stable or Progress to Incomplete Lupus or Classified SLE in the Lupus Autoimmunity in Relatives (LAUREL) Follow-up Cohort
Melissa Munroe¹, Kendra Young², Jill Norris³, Joel Guthridge⁴, Diane Kamen⁵, Timothy Niewold⁶, Gary Gilkeson⁷, Michael Weisman⁸, Mariko Ishimori⁹, Daniel Wallace¹⁰, David Karp¹¹, John Harley¹² and Judith James¹³, ¹Oklahoma Medical Research Foundation/Progentec Diagnostics, Inc., Oklahoma City, OK, ²University of Colorado Denver, Aurora, CO, ³Colorado School of Public Health, Aurora, CO, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Medical University of South Carolina, Charleston, SC, ⁶NYU School of Medicine, New York, NY, ⁷Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁸Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, LOS ANGELES, CA, ⁹Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Cedars-Sinai Medical Center/UCLA, Los Angeles, CA, ¹¹UT Southwestern Medical Center, Dallas, TX, ¹²Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Cincinnati, OH, ¹³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK
Background/Purpose: Identifying populations at risk of SLE is essential to curtail inflammatory damage and identify individuals for prevention trials. Unaffected blood relatives (BRs) of lupus…
Abstract Number: 1506 • ACR Convergence 2020
Correction of Sjögren’s Syndrome Fluid Secretion Deficits in Salivary Gland Acinar Cells by Aquaporin-1 Gene Transfer
Paola Perez¹, Blake Warner², Sandra Wainer¹, Youngmi Ji¹, Thomas Pranzatelli¹ and Jay Chiorini¹, ¹Nidcr, National Institute of Health, Bethesda, MD, ²National Institute of Dental and Craniofacial Research, Bethesda
Background/Purpose: The hallmark clinical complaints in Sjögren’s syndrome (SS) are dry mouth and dry eyes related to salivary and lacrimal glands dysfunction. Reduced salivation reflects…
Abstract Number: 1517 • ACR Convergence 2020
Metabolic Regulation of Type 3 Innate Lymphoid Cells by Intestinal Bacteria-Derived Indoles in Ankylosing Spondylitis
Adam Berlinberg¹, Adam Lefferts², Emilie Regner³, Andrew Stahly⁴ and Kristine Kuhn⁴, ¹University of Colorado, Denver, CO, ²University of Colorado, Anschutz Medical Campus, Denver, CO, ³University of California San Francisco, San Francisco, CA, ⁴University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: Intestinal microbial dysbiosis, intestinal inflammation, and Th17 immunity are all linked to the pathophysiology of ankylosing spondylitis (AS); however, the mechanisms linking them remain…
Abstract Number: 1514 • ACR Convergence 2020
The Impact of Renal Transplantation on Cardiovascular Events Among Patients with End-State Kidney Disease Due to Lupus Nephritis: A Nationwide Cohort Study
April Jorge¹, Xiaoqing Fu², Yuqing Zhang³, Hyon Choi⁴ and Zachary Wallace⁵, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Harvard Medical School, Boston, ⁴Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA, ⁵Harvard Medical School, Boston
Background/Purpose:A major complication of systemic lupus erythematosus (SLE) is the progression of lupus nephritis (LN) to end-stage kidney disease (ESKD). Both SLE and ESKD are…
Abstract Number: 1509 • ACR Convergence 2020
Leukocyte Telomere Length and Childhood Onset of Systemic Lupus Erythematosus in the Black Women’s Experiences Living with Lupus (BeWELL) Study
John Bridges¹, Kara Chung², Connor Martz², Emily Smitherman¹, Cristina Drenkard³, S. Sam Lim⁴ and David Chae², ¹University of Alabama at Birmingham, Birmingham, AL, ²Auburn University, Auburn, AL, ³Division of Rheumatology, Department of Medicine, Emory School of Medicine, Atlanta, GA, ⁴Emory University, Atlanta, GA
Background/Purpose: Childhood-onset SLE is generally more aggressive than adult-onset SLE. Leukocyte telomere length (LTL) has been posited to reflect immune system aging. Short LTL in…
Abstract Number: 1401 • ACR Convergence 2020
Disease Mutation That Weakens ZAP70 Autoinhibition Enhances Responses to Weak and Self Ligands
Lin Shen¹, Mehrdad Matloubian¹, Theresa Kadlecek² and Arthur Weiss¹, ¹University of California, San Francisco, San Francisco, CA, ²University of California, San Francisco, San Francisco
Background/Purpose: ZAP70, a cytoplasmic protein tyrosine kinase, is critical for TCR signaling and T cell development. Complete loss of function of ZAP70 in humans causes…
Abstract Number: 1276 • ACR Convergence 2020
Using Classification and Regression Tree Analysis to Assess the Construct Validity of the Automated Neuropsychological Assessment Metrics in the Assessment of Cognitive Impairment in SLE Compared to the ACR Neuropsychological Battery
Kimberley Yuen¹, Dorcas Beaton², Kathleen Bingham³, Jiandong Su⁴, Mahta Kakvan⁴, Juan Pablo Diaz-Martinez⁴, Carmela Tartaglia⁵, Lesley Ruttan⁶, Joan Wither⁴, Nicole Anderson⁴, Dennisse Bonilla⁴, May Choi⁷, Marvin Fritzler⁸, Patricia Katz⁹, Robin Green⁶ and Zahi Touma¹⁰, ¹Queen's University School of Medicine; University of Toronto Lupus Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, Canada, ²Institute for Work & Health, Toronto, ON, Canada, ³Department of Psychiatry, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁵University of Toronto, Krembil Neurosciences Centre, Toronto, ON, Canada, ⁶Toronto Rehabilitation Institute, University Health Network, Toronto, ON, Canada, ⁷Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁸Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁹University of California, San Francisco, Novato, CA, ¹⁰University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network; Krembil Research Institute, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is common in systemic lupus erythematosus (SLE) patients, however there is no standard screening tool available. The American College of Rheumatology…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].